Sanofi (SNY) to Release Earnings on Friday

Key Points

• Sanofi is set to announce its Q3 2025 earnings on October 24, 2025, with analysts projecting earnings of $1.65 per share and revenue of $12.6208 billion.
• The company recently reported a decrease of 7.0% in year-over-year revenue, with a last quarter EPS of $0.90, falling short of the consensus estimate of $0.96.
• Analysts maintain a generally positive outlook on Sanofi, with an average rating of "Buy" and a consensus price target of $62.67.

Sanofi (NASDAQ:SNY - Get Free Report) is expected to be posting its Q3 2025 results before the market opens on Friday, October 24th. Analysts expect Sanofi to post earnings of $1.65 per share and revenue of $12.6208 billion for the quarter. Interested persons may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Friday, October 24, 2025 at 8:30 AM ET.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). The company had revenue of $11.34 billion for the quarter, compared to analysts' expectations of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.Sanofi's revenue for the quarter was down 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.73 earnings per share. On average, analysts expect Sanofi to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $50.02 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. Sanofi has a one year low of $44.62 and a one year high of $60.12. The company's fifty day moving average is $48.42 and its two-hundred day moving average is $49.65. The firm has a market capitalization of $122.82 billion, a P/E ratio of 12.02, a PEG ratio of 1.19 and a beta of 0.51.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on SNY. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday, August 8th. Wall Street Zen upgraded Sanofi from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Barclays reiterated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Tuesday, September 2nd. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Sanofi in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $62.67.

Hedge Funds Weigh In On Sanofi

Several institutional investors have recently added to or reduced their stakes in SNY. EverSource Wealth Advisors LLC increased its holdings in shares of Sanofi by 36.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company's stock worth $159,000 after buying an additional 875 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Sanofi by 243.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,450 shares of the company's stock valued at $215,000 after acquiring an additional 3,154 shares during the period. IHT Wealth Management LLC purchased a new stake in Sanofi during the second quarter valued at about $239,000. EP Wealth Advisors LLC lifted its stake in shares of Sanofi by 11.3% in the 2nd quarter. EP Wealth Advisors LLC now owns 5,323 shares of the company's stock valued at $257,000 after purchasing an additional 540 shares in the last quarter. Finally, Brighton Jones LLC lifted its stake in shares of Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after purchasing an additional 1,869 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.